Proteomics International Laboratories has won a U.S. patent for its endometriosis test, facilitating the rollout of the diagnostic product in the United States [1].
This development is significant because it allows the company to enter the world’s biggest healthcare market [1] with a non-invasive method for diagnosing a condition that often requires lengthy clinical delays.
The product, known as PromarkerEndo, is a diagnostic blood test designed to identify endometriosis [3]. By securing this intellectual property, the company aims to streamline the process of detecting the condition through a simple blood draw rather than more invasive surgical procedures.
In addition to the U.S. approval, the company has secured a patent from the Japan Patent Office for PromarkerEndo [3]. This ensures intellectual property protection across two major global markets as the company expands its commercial footprint [3].
"Proteomics International Laboratories has won a US patent for its endometriosis test, advancing plans to roll out the diagnostic product in the world’s biggest healthcare market," MSN said [2].
The Japanese patent further reinforces the company's strategy to protect its proprietary technology while scaling the availability of the test. Yahoo Finance said the company secured the Japan Patent Office approval to ensure intellectual property protection [3].
“Proteomics International Laboratories has won a US patent for its endometriosis test”
The acquisition of patents in both the U.S. and Japan removes significant legal hurdles for Proteomics International Laboratories, allowing it to commercialize PromarkerEndo in high-value markets. By transitioning endometriosis diagnosis from invasive surgery to a blood-based biomarker test, the company is positioned to disrupt the current diagnostic standard and potentially reduce the time to treatment for patients globally.
